Turnaround Time for Biotech?
640990
Now might be a great time to load up on cutting-edge drug makers.
347902
Investors might be willing to forgive Tellabs (Nasdaq: TLAB) for missing expectations on its latest Q3 earnings. These things happen, especially when there are extenuating circumstances.
644886
THERE is never a right time to buy technology. Something cheaper, faster and better specified will be on the market before you have even got your product out of its box.
519863
The company faces a pivotal clinical trial.
182389
After a quiet year for biotechnology, a sudden wave of mergers and buyouts has sparked interest in a business that relies on deal-making to put the stamp of success on new ideas.
504116
Alantos Pharmaceuticals Inc., a Cambridge biotech company sold to Amgen Inc. for $300 million in July, plans to shut down and eliminate its 45 jobs in Massachusetts and Germany, said Amgen spokeswoman Mary Klem. Amgen, based in Thousand Oaks, Calif., has another 200 workers in Cambridge. The drug maker is offering voluntary buyouts to its older and long-term employees - ...
51447
Millionaires' club sets genome target A $10m carrot is being dangled at biotech firms to encourage them to redouble efforts to make genome sequencing available to individuals.â¦
581158
Canada's biotech sector may finally be  on the road to a sustained recovery after a series of  short-lived remissions.
760357
Biotech funds differ in their make-up, performance, and promise.
392067
Boston Life Sciences Inc. said it is seeking the approval of shareholders for a reverse stock split of its issued and outstanding common shares. According to a proxy statement filed with the Securities and Exchange Commission, the company seeks approval for any of a 1-for-5, 1-for-10, or 1-for-15 reverse stock spilt at its annual meeting Jan. 28. Boston Life Sciences ...
265725
Turnarounds are great ... when they actually turn around.
704677
Washington area biotech companies will face pivotal moments this year, finding out whether key products work before money dries up, fending off competition from bigger companies,  and, perhaps filing to go public.
145474
Looking over all the biotech stock stories I covered in 2004, I&#39;m pleased to report that I was right more than wrong. My &quot;win&quot; column does veer in the bearish direction, which is not ideal (I&#39;d prefer more
343462
The company has to confront concerns over genetically modified foods soon if it hopes to keep growing.
320472
Fool Paul Elliott takes a chance on biotech -- with somebody else's money.
738382
The drug maker is poised to speed past its rivals.
554623
By Mowad, Michelle  The local biotechnology and technology industries, highly dependent on very highly skilled workers, are waiting to see if their foreign job applicants have been awarded work visas.  U.S.